

22. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, et al. (2002) European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 61: 554–558.
23. Miyaji M, Jin ZX, Yamaoka S, Amakawa R, Fukuhara S, et al. (2005) Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. *J Exp Med* 202: 249–259.
24. Wakamatsu E, Matsumoto I, Yasukochi T, Naito Y, Goto D, Mamura M, et al. (2006) Overexpression of phosphorylated STAT-1alpha in the labial salivary glands of patients with Sjögren's syndrome. *Arthritis Rheum* 54: 3476–3484.
25. van Woerkom JM, Kruize AA, Wenting-van Wijk MJG, Knol E, Bihari IC, et al. (2005) Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non-Sjögren's sicca syndrome. *Ann Rheum Dis* 64: 1474–1479.
26. Yoshimura A, Wakabayashi Y, Mori T (2010) Cellular and molecular basis for the regulation of inflammation by TGF-beta. *J Biochem* 147: 781–792.
27. Romagnani S (2008) Human Th17 cells. *Arthritis Res Ther* 10: 206.
28. Naka T, Nishimoto N, Kishimoto T (2002) The paradigm of IL-6: from basic science to medicine. *Arthritis Res* 4 Suppl 3: S233–S242.
29. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, et al. (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. *Blood* 106: 2627–2632.
30. Katsifis GE, Reka S, Moutsopoulos NM, Pillemer S, Wahl SM (2009) Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. *Am J Pathol* 175: 1167–1177.
31. Szyszko EA, Brokstad KA, Ojordshakken G, Jonsson MV, Jonsson R, et al. (2011) Salivary glands of primary Sjögren's syndrome patients express factors vital for plasma cell survival. *Arthritis Res Ther* 13: R2.

